<DOC>
	<DOCNO>NCT00259753</DOCNO>
	<brief_summary>The objective study evaluate safety preliminary efficacy three dos Cand5 . Cand5 , small interfere RNA molecule selectively silence mRNA encode VEGF .</brief_summary>
	<brief_title>Safety Efficacy Study Small Interfering Ribonucleic Acid ( RNA ) Molecule ( Cand5 ) Treat Wet Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<criteria>1 . Patients must subfoveal classic , predominantly classic , minimally classic lesion , secondary AMD . 2 . Patients must ETDRS best correct visual acuity 64 24 letter ( 20/50 20/320 Snellen Equivalent ) study eye . 3 . Patients must age 50 old 1 . Patients receive prior treatment investigational new drug device wet AMD study eye within 24 week screen visit . 2 . Patients advanced glaucoma ( great 0.8 cup : disk ) intraocular pressure 22 mmHg study eye . 3 . Patients retinal vasculopathies , include diabetic retinopathy , retinal vein occlusion , etc . study eye . 4 . Patients subfoveal scarring , atrophy , hemorrhage study eye . 5 . Patients whose CNV lesion study eye contain 25 % scar and/or atrophy . 6 . Patients undergone extrafoveal/juxtafoveal laser treatment study eye within two week prior screen visit . 7 . Patients receive treatment investigational drug within 4 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Wet Age-Related Macular Degeneration</keyword>
</DOC>